NRD
AMLX icon

Nebula Research & Development’s Amylyx Pharmaceuticals AMLX Stock Holding History

Nebula Research & Development’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-57,850
Closed -$852K – 728
2023
Q4 		$852K Buy
57,850
+29,828
+106% +$457K 0.26% 102
2023
Q3 		$513K Buy
+28,022
New +$593K 0.27% 125

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nebula Research & Development's AMLX Position: Q1 2024 in Review

Nebula Research & Development sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 57,850 shares — an estimated $852K sold.

Nebula Research & Development first reported a position in AMLX in Q3 2023 and held it in 2 quarters. The position peaked at $852K in Q4 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • Nebula Research & Development reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Nebula Research & Development sold 57,850 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $852K.
  • Nebula Research & Development first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Nebula Research & Development's Amylyx Pharmaceuticals position peaked at $852K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Nebula Research & Development's 13F filing for Q1 2024, filed 15 May 2024.